HeartRhythm secures nearly 100 million RMB in Series A funding to fully establish a mechanical circulatory support technology platform for heart failure.

Shanghai Dynaheart Medical Technology Co., Ltd. (Dynaheart) has closed nearly 100 million RMB in Series A funding, led by IDG Capital with participation from Huage Capital and Langmafeng Capital. The funds will be primarily used for the clinical trials required to register the company's first product, the OmniHeart percutaneous ventricular assist device, as well as to accelerate the research, development, clinical trials, and commercialization of its existing product line and new products.

As the fastest-growing company in heart failure product development, Dynaheart Medical was founded in 2021 in Minhang District, Shanghai, with a focus on the R&D and commercialization of innovative medical devices for heart failure. We are committed to providing comprehensive, safe, and effective intelligent mechanical circulatory support solutions for heart failure patients. In clinical practice, the disease progression varies among heart failure patients, leading to different needs for mechanical circulatory support at each stage. To address this, HeartConstant has innovatively developed percutaneous ventricular assist devices, implantable ventricular assist devices, and implantable biventricular assist devices—creating a three-in-one solution tailored for Chinese patients. Our flagship product, Omniheart Percutaneous Ventricular Assist Device, exemplifies the "HeartConstant Speed," completing the transition from R&D to clinical application in just 2 years. It is the first device of its kind successfully used in clinical research trials in China and is poised to lead large-scale confirmatory clinical studies.

Rigorous and efficient, uniting a professional team.

Dr. Huang Lin, the company's founder, graduated from Harbin Institute of Technology and Beihang University. With 10 years of experience in medical device R&D, he has held leadership roles at top domestic and international companies including Medtronic, leading and contributing to the development of multiple Class III medical devices.

Co-founder Mr. Jiang Haiyang holds both bachelor's and master's degrees from Tsinghua University and has 15 years of experience in the aerospace and medical device industries. He previously served as a Senior Project Manager at MicroPort CardioFlow, leading the development of the transcatheter aortic valve replacement (TAVR) project. Our core team members collectively possess over 10 years of experience in healthcare or related fields, with expertise spanning fluid dynamics, mechanical engineering, electronics, software, and materials science.

Comprehensive portfolio of implantable and interventional artificial hearts, delivering one-stop mechanical circulatory support solutions.

Leveraging its core technology platform, Dynaheart Medical has developed a multi-product pipeline in the mechanical circulatory support field for heart failure. For patients at any stage of heart failure, Dynaheart provides personalized ventricular assist devices for effective treatment. Its percutaneous ventricular assist device series offers effective short-to-medium-term circulatory support for high-risk clinical scenarios such as PCI, cardiogenic shock, acute myocardial infarction, cardiorenal syndrome, and right-sided heart failure. For refractory end-stage heart failure, long-term implantable ventricular assist devices enable bridge-to-transplant or durable therapy. In the future, Dynaheart will also launch dual-ventricular assist devices and total artificial hearts to treat patients with biventricular heart failure.

Overcoming core technical barriers and filling a domestic gap, the implantable ventricular assist device is set to launch clinical trials for registration.

OmniHeart is a percutaneous ventricular assist device independently developed by Dynaheart Medical. It features fully independent intellectual property rights and offers significant advantages across multiple dimensions:

1. Efficient fluid design with high flow rates (above 4.0L/min). Notably, its hemolysis index (NIH) is reduced by 90% compared to industry standards, minimizing blood damage and delivering superior product performance.
2. A fully proprietary micro-implantable motor with compact size, high power density, excellent biocompatibility, and high reliability. It delivers sustained, stable operation for over 7 days, meeting treatment needs for patients undergoing high-risk PCI and most cases of cardiogenic shock.
3. Intelligent Safety Monitoring System: Uses built-in algorithms to determine blood pump position and operational status, enhancing safety during continuous operation in non-OR settings (e.g., ICU, transport) to better meet clinical needs.

According to Dr. Huang Lin, founder of XinHengRui, developing the percutaneous ventricular assist device (pVAD) presents challenges beyond fluid dynamics design—such as impeller configuration and hemodynamics. It also requires solving critical issues related to the implantable micro-motor itself, including reliability, durability, biocompatibility, and thermal management. The product has already secured multiple core patents and is currently undergoing the NMPA's Special Review Program for Innovative Medical Devices.

Heart failure is often called "the final battlefield of heart disease," characterized by high incidence and mortality rates, as well as poor prognosis. Statistics show that the prevalence of heart failure reaches 20% among people aged 70-80, with 50% of patients dying within 5 years of diagnosis. As survival rates for conditions such as heart disease and diabetes improve and populations age globally, the number of heart failure patients is projected to continue rising. Xinhongrui's self-developed OmniHeart percutaneous ventricular assist device offers a promising new dawn in treatment for heart failure patients worldwide.

Investor Message

Regarding this financing round, Dr. Huang Lin, Founder of Dynaheart Medical, stated: "We are deeply grateful to all investors for their trust and support in Dynaheart Medical. This successful funding will accelerate the high-quality development of our product portfolio. Rooted in China, we remain committed to addressing the clinical needs of Chinese patients. We have the responsibility, confidence, and capability to bring the latest global technologies and cutting-edge products to more patients. By building a mechanical assistance platform driven by innovation synergy and clinical demand alignment, we will continue to deepen our expertise in heart failure treatment and better serve heart failure patients across China."

Mr. Liu Yikun, Partner at IDG Capital, stated: "Heart failure is the only cardiovascular disease with a growing global prevalence. As an innovative medical device company providing comprehensive mechanical circulatory support solutions, Dynaheart Medical has achieved remarkable results within its first two years of operation. Building on our innovative technology platform and driven by professional rigor and clinical needs, we have efficiently advanced the R&D and clinical development of multiple product lines. This gives us strong confidence in Dynaheart Medical's future. IDG Capital is delighted to partner with Dynaheart Medical to deliver safer, more effective, and accessible premium medical products for heart failure patients in China and worldwide, offering personalized heart failure solutions tailored to China."

Dr. Du Jiangbo, Managing Partner at Wager Capital, stated: "With the rise in PCI procedures, CTO lesion interventions require more advanced circulatory support devices. Currently, the high mortality rate of cardiogenic shock remains an urgent clinical challenge. As large-scale global clinical evidence continues to emerge, we believe interventional circulatory support devices will become a key tool for managing heart failure. Dynaheart Medical is a significant player in this space, with a highly execution-oriented team, strong collaboration, and solid technical expertise. The company possesses a comprehensive platform technology stack and in-house capabilities for core component development, offering a rich pipeline of future products. We are delighted to partner with Dynaheart Medical and will leverage our industry resources to accelerate the development and market launch of innovative medical devices tailored to China's clinical needs, ultimately benefiting patients."

Mr. Yu Tiandong, Partner at Langma Capital, stated: "As the startup with the fastest pVAD development progress, HeartRhythm's team spans multiple disciplines including motors, materials, fluid dynamics, mechanics, and electronic control, demonstrating exceptional R&D capabilities. Our products are built on core proprietary intellectual property with controllable costs, positioning us for strong commercial competitiveness. We hope our product will receive approval as soon as possible to benefit patients both domestically and internationally, and we are pleased to participate in the company's Series A financing."

About Everest Capital

Lingma Venture Capital has been operating for over 15 years, with investments in more than 200 companies and assets under management exceeding 10 billion yuan. We specialize in hard-tech investing, uphold value investment principles, and are committed to helping investors share in the growth of the world's most exceptional enterprises.